Cayston Side Effects

Generic name: aztreonam

Medically reviewed by Drugs.com. Last updated on Jun 30, 2024.

Note: This document provides detailed information about Cayston.

Applies to aztreonam: inhalation powder for reconstitution, injectable powder for injection, intravenous solution Side Effects associated with aztreonam. Some dosage forms listed on this page may not apply specifically to the brand name Cayston.

Applies to aztreonam: inhalation powder for reconstitution, injectable powder for injection, intravenous solution.

General

Aztreonam (the active ingredient contained in Cayston) for injection was generally well tolerated. The overall incidence of systemic side effects was about 1% to 1.3%.^[Ref]

Respiratory

Aztreonam (the active ingredient contained in Cayston) for inhalation:

• Very common (10% or more): Cough (54%), nasal congestion (16%), wheezing (16%)
• Common (1% to 10%): Bronchospasm (3%)
• Postmarketing reports: Dyspnea

Aztreonam for injection:

• Uncommon (0.1% to 1%): Less than 1%: Wheezing, dyspnea, chest pain, sneezing, nasal congestion^[Ref]

Other

Aztreonam (the active ingredient contained in Cayston) for inhalation:

• Very common (10% or more): Pyrexia (13%), pharyngolaryngeal pain (12%)
• Common (1% to 10%): Chest discomfort (8%), abdominal pain (7%)

Aztreonam for injection:

• Common (1% to 10%): Superinfection (up to 10%)
• Uncommon (0.1% to 1%): Less than 1%: Weakness, fever, malaise, flushing^[Ref]

Superinfection has been reported in up to 10% of patients during aztreonam therapy and was usually due to enterococcus or staphylococcus.^[Ref]

Gastrointestinal

Aztreonam (the active ingredient contained in Cayston) for inhalation:

• Common (1% to 10%): Vomiting (6%)

Aztreonam for injection:

• Common (1% to 10%): 1% to 1.3%: Nausea, vomiting, diarrhea
• Uncommon (0.1% to 1%): Less than 1%: Abdominal cramps, mouth ulcer, altered taste, numb tongue, halitosis
• Rare (less than 0.1%): Clostridium difficile associated diarrhea, pseudomembranous colitis, gastrointestinal bleeding^[Ref]

Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.^[Ref]

Dermatologic

Aztreonam (the active ingredient contained in Cayston) for inhalation:

• Common (1% to 10%): Rash (2%)

Aztreonam for injection:

• Common (1% to 10%): Rash (1% to 1.3%)
• Uncommon (0.1% to 1%): Less than 1%: Toxic epidermal necrolysis, purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis^[Ref]

Toxic epidermal necrolysis associated with aztreonam has been reported in very ill patients on many other medications, making implication of aztreonam difficult.^[Ref]

Local

Aztreonam (the active ingredient contained in Cayston) for injection:

• Common (1% to 10%): Discomfort/swelling at the injection site after intramuscular administration (2.4%), phlebitis/thrombophlebitis after intravenous administration (1.9%)^[Ref]

Hypersensitivity

Aztreonam (the active ingredient contained in Cayston) for inhalation:

• Frequency not reported: Allergic reaction (with facial rash, facial swelling, throat tightness)

Aztreonam for injection:

• Uncommon (0.1% to 1%): Less than 1%: Anaphylaxis, angioedema, bronchospasm
• Rare (less than 0.1%): Maculopapular eruption (at least 1 case)^[Ref]

A 57-year-old male developed a widespread maculopapular eruption two hours after receiving aztreonam. Corticosteroids and antihistamines were needed to control the reaction which disappeared after 8 days. The patient also showed cross-reactivity to ceftazidime which shares the same side chain as aztreonam.^[Ref]

Hematologic

Aztreonam (the active ingredient contained in Cayston) for injection:

• Uncommon (0.1% to 1%): Less than 1%: Pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis
• Frequency not reported: Increased prothrombin time, increased partial thromboplastin time, positive Coombs' test^[Ref]

A case of myelosuppression associated with aztreonam has been reported, but because many other drugs were administered and because the patient was bacteremic, implication of aztreonam as the causative agent was difficult.

In vitro studies have shown that aztreonam may inhibit ADP-induced platelet aggregation at high concentrations. Clinically, therapeutic doses of aztreonam have not been associated with bleeding problems.^[Ref]

Hepatic

Aztreonam (the active ingredient contained in Cayston) for injection:

• Uncommon (0.1% to 1%): Less than 1%: Hepatitis, jaundice, signs or symptoms of hepatobiliary dysfunction
• Frequency not reported: Elevated AST, elevated ALT, elevated alkaline phosphatase^[Ref]

Cardiovascular

Aztreonam (the active ingredient contained in Cayston) for injection:

• Uncommon (0.1% to 1%): Hypotension (less than 1%), transient electrocardiogram changes (ventricular bigeminy, premature ventricular contractions; less than 1%)^[Ref]

Nervous system

Aztreonam (the active ingredient contained in Cayston) for injection:

• Uncommon (0.1% to 1%): Less than 1%: Seizure, headache, confusion, vertigo, paresthesia, insomnia, dizziness, tinnitus^[Ref]

Musculoskeletal

Aztreonam (the active ingredient contained in Cayston) for inhalation:

• Postmarketing reports: Arthralgia, joint swelling

Aztreonam for injection:

• Uncommon (0.1% to 1%): Muscular aches (less than 1%)^[Ref]

Renal

Aztreonam (the active ingredient contained in Cayston) for injection:

• Rare (less than 0.1%): Acute interstitial nephritis (at least 1 case)
• Frequency not reported: Increased serum creatinine^[Ref]

Acute interstitial nephritis associated with aztreonam has been reported in a very ill patient receiving many other medications.^[Ref]

Genitourinary

Aztreonam (the active ingredient contained in Cayston) for injection:

• Uncommon (0.1% to 1%): Less than 1%: Vaginal candidiasis, vaginitis, breast tenderness^[Ref]

Ocular

Aztreonam (the active ingredient contained in Cayston) for injection:

• Uncommon (0.1% to 1%): Diplopia (less than 1%)^[Ref]

Further information

Cayston side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer